Isotechnika buoyed by deal with Vifor for voclosporin in lupus
This article was originally published in Scrip
Executive Summary
Isotechnika's share price rose by 12.5% to Can$0.135 after the Canadian firm announced that it had licensed out its lead drug for a secondary indication. Vifor Pharma, the speciality pharma business of Swiss firm Galenica, has acquired rights to voclosporin for lupus and all proteinuric nephrology indications; Isotechnika is developing it primarily for the prevention of kidney transplant rejection.